Evidence map›Paper›PMID 32536651›Full record

ArticleInternal medicine (Tokyo, Japan)2020

Dasatinib-induced Nonspecific Interstitial Pneumonia That Developed 7 Years after the Initiation of Dasatinib.

Daisuke Takekoshi, Yuma Matsui, Takuya Akutsu, Ayako Nishioka, Ayu Kiritani, Keitaro Okuda, Junko Watanabe, Hanae Miyagawa, Hirohumi Utsumi, Mitsuo Hashimoto and 10 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Daisuke TakekoshiDivision of Respiratory Medicine, Department of Internal Medicine, Jikei University School of Medicine, Japan.
Yuma MatsuiDivision of Respiratory Medicine, Department of Internal Medicine, Jikei University School of Medicine, Japan.
Takuya AkutsuDivision of Respiratory Medicine, Department of Internal Medicine, Jikei University School of Medicine, Japan.
Ayako NishiokaDivision of Respiratory Medicine, Department of Internal Medicine, Jikei University School of Medicine, Japan.
Ayu KiritaniDivision of Respiratory Medicine, Department of Internal Medicine, Jikei University School of Medicine, Japan.
Keitaro OkudaDivision of Respiratory Medicine, Department of Internal Medicine, Jikei University School of Medicine, Japan.
Junko WatanabeDivision of Respiratory Medicine, Department of Internal Medicine, Jikei University School of Medicine, Japan.
Hanae MiyagawaDivision of Respiratory Medicine, Department of Internal Medicine, Jikei University School of Medicine, Japan.
Hirohumi UtsumiDivision of Respiratory Medicine, Department of Internal Medicine, Jikei University School of Medicine, Japan.
Mitsuo HashimotoDivision of Respiratory Medicine, Department of Internal Medicine, Jikei University School of Medicine, Japan.
Hiroshi WakuiDivision of Respiratory Medicine, Department of Internal Medicine, Jikei University School of Medicine, Japan.
Shunsuke MinagawaDivision of Respiratory Medicine, Department of Internal Medicine, Jikei University School of Medicine, Japan.
Hiromichi HaraDivision of Respiratory Medicine, Department of Internal Medicine, Jikei University School of Medicine, Japan.
Takanori NumataDivision of Respiratory Medicine, Department of Internal Medicine, Jikei University School of Medicine, Japan.
Yuki NodaDivision of Thoracic Surgery, Department of Surgery, Jikei University School of Medicine, Japan.
Rei MakishimaDepartment of Pathology, Jikei University School of Medicine, Japan.
Masahiro IkegamiDepartment of Pathology, Jikei University School of Medicine, Japan.
Yoshinori KawabataDepartment of Pathology, Saitama Cardiovascular and Respiratory Center, Japan.
Jun ArayaDivision of Respiratory Medicine, Department of Internal Medicine, Jikei University School of Medicine, Japan.
Kazuyoshi KuwanoDivision of Respiratory Medicine, Department of Internal Medicine, Jikei University School of Medicine, Japan.
Jikei University School of Medicine · JPSaitama Prefecture · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the case of a 56-year-old man with chronic myeloid leukemia (CML) who developed dasatinib-induced interstitial lung disease (ILD) 7 years after starting dasatinib, a BCR-ABL1 inhibitor. The patient presented with dyspnea. Chest imaging showed diffuse ground-glass opacities. A surgical lung biopsy showed cellular non-specific interstitial pneumonia (NSIP). Corticosteroid treatment ameliorated his condition. Bosutinib, another BCR-ABL1 inhibitor, was successfully re-instituted. The present case and relevant literature suggest that dasatinib-induced ILD can present as NSIP after an extended period, responds to corticosteroids, and is amenable to re-challenge at a lower-dose or with alternative BCR-ABL1 inhibitors.

Indexed as

DasatinibHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLungLung Diseases, InterstitialMaleMiddle AgedProtein Kinase InhibitorsDasatinibProtein Kinase Inhibitorschronic myeloid leukemiadasatinibinterstitial lung diseasenon-specific interstitial pneumonia

Identifiers

PMID32536651
PMCPMC7578610
OpenAlexW3034774114

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.